IRS1抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Mouse liver tissue, Primary antibody: P08589(OTC Antibody) at dilution 1/650, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 second    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P08589(OTC Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P08589(OTC Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

The insulin receptor substrate 1 (IRS1) antibody is a crucial tool in studying the IRS1 protein, a key mediator in insulin and insulin-like growth factor 1 (IGF-1) signaling pathways. IRS1. a cytoplasmic adaptor protein, facilitates signal transduction from activated insulin/IGF-1 receptors to downstream effectors like PI3K-AKT and MAPK, regulating glucose metabolism, cell growth, and survival. Dysregulation of IRS1 is linked to insulin resistance, type 2 diabetes, obesity, and cancers, making it a focal point in metabolic and oncological research.

IRS1 antibodies are widely used in techniques such as Western blotting, immunohistochemistry (IHC), and immunoprecipitation to detect IRS1 expression, phosphorylation status, and interaction partners. These antibodies help elucidate IRS1's role in cellular responses under physiological and pathological conditions, including its post-translational modifications (e.g., serine/threonine phosphorylation) that modulate its activity.

Available as monoclonal or polyclonal forms, IRS1 antibodies vary in specificity and applications. Monoclonal antibodies offer consistency for quantitative assays, while polyclonal antibodies may detect multiple epitopes, enhancing sensitivity for low-abundance targets. Validation using IRS1 knockout models or siRNA knockdown is critical to confirm antibody specificity.

Commercially sourced from suppliers like Cell Signaling Technology, Abcam, and Santa Cruz Biotechnology, these antibodies drive advancements in understanding metabolic disorders and cancer mechanisms, aiding therapeutic target discovery.